Why are American drug prices so high?

Key Concepts

• WGOI: A weight loss drug.
• Most Favored Nation (MFN) Pricing: A proposed policy by Donald Trump to peg US drug prices to the lowest prices charged in other rich countries.
• Pharmacy Benefit Managers (PBMs): Middlemen in the US drug supply chain who negotiate with drug makers and insurers.
• Drug Development Costs: Significant investment in research and development, with a high failure rate.
• Rebates and Discounts: Reductions in drug prices offered by manufacturers to PBMs and insurers.

Donald Trump's "Most Favored Nation" Pricing Proposal

The video discusses Donald Trump's dissatisfaction with high drug prices in America, specifically highlighting the example of WGOI, which costs approximately $135 per month in Britain but ten times that amount in the US. Trump's proposed solution is "most favored nation pricing," a policy aimed at forcing drug companies to set US prices based on the lowest prices charged in other developed nations.

Supporting Evidence for the Problem:

• America accounts for about half of global pharmaceutical sales but generates 70% of profits.
• Americans pay more than three times the average price of drugs in other rich countries.

The US Drug Market Structure and its Impact on Pricing

The transcript explains that the high prices in the US are attributed to the market's organization.

• Other Countries: Governments directly negotiate with drug makers, leveraging their bargaining power to secure lower prices.
• United States: Prices are determined through a complex system of contracts and negotiations involving drug makers, insurers, and middlemen like Pharmacy Benefit Managers (PBMs).

Issue with Middlemen (PBMs):

• PBMs are often compensated as a percentage of the list price.
• This payment structure creates little incentive for them to reduce costs.

Potential Negative Consequences of MFN Pricing

The video argues that Trump's MFN pricing plan could have unintended negative consequences.

• Risk of Reduced Drug Access: Pharma companies might raise prices in other countries to increase the benchmark, or alter formulations to complicate international comparisons.
• Delayed Drug Launches: Companies could delay launching new drugs in cheaper markets altogether.
• Limited Impact on US Prices: These strategies would not necessarily make drugs cheaper for Americans.
• Evidence from Europe: A 2023 study indicated that similar rules in Europe delayed drug launches in poorer countries, with little effect on US prices and limited access to new drugs in lower-income countries.

The Role of Pharmaceutical Innovation and Research Costs

The transcript acknowledges that the high cost of drugs is not solely the fault of pharmaceutical companies.

• High R&D Investment: Drug makers undertake significant, risky investments in developing new treatments, which can take decades and billions of dollars.
• High Failure Rate: Approximately 90% of clinical drug development projects fail.
• Need for Cost Recovery: Companies need to recoup their costs on successful drugs to reinvest in future cures. Slashing profits could hinder innovation.

Identifying the "Real Problem" in the US Drug Market

The video suggests that the primary issue lies elsewhere in the supply chain.

• 2024 Data: Drug sales in America surpassed $1 trillion.
• Manufacturer vs. Middlemen Share: Manufacturers received less than half of this amount after discounts and rebates. The remaining portion went to middlemen.
• Proposed Solution: Encouraging more competition within the rest of the supply chain is presented as a more effective way to lower consumer prices without jeopardizing innovation.

Conclusion

The summary concludes that while America's drug market is indeed "broken," Trump's proposed cure of MFN pricing could potentially be "worse than the disease," leading to unintended negative consequences for drug access and affordability. The transcript advocates for addressing issues within the broader supply chain to achieve more sustainable price reductions.